Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA

Hong Yeol Yoon; Sejin Son; So Jin Lee; Dong Gil You; Ji Young Yhee; Jae Hyung Park; Maggie Swierczewska; Seulki Lee; Ick Chan Kwon; Sun Hwa Kim; Kwangmeyung Kim; Martin G. Pomper

doi:10.1038/srep06878

Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA

Hong Yeol Yoon, Sejin Son, So Jin Lee, Dong Gil You, Ji Young Yhee, Jae Hyung Park, Maggie Swierczewska, Seulki Lee, Ick Chan Kwon, Sun Hwa Kim, Kwangmeyung Kim, Martin G. Pomper

Medicine - Pulmonary, Allergy, Critical

Research output: Contribution to journal › Article › peer-review

124 Scopus citations

Abstract

Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and possibly synergistic mechanisms. In this respect, glycol chitosan (GC)-based nanoparticles (CNPs) serve as an effective platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy by overcoming resistance. Herein, DOX-encapsulated CNPs (DOX-CNPs) or Bcl-2 siRNA-encapsulated CNPs (siRNA-CNPs) exhibited similar physicochemical properties, including size, surface properties and pH sensitive behavior, regardless of the different physical features of DOX and Bcl-2 siRNA. We confirmed that the CNP platform applied to two different types of drugs results in similar in vivo biodistribution and pharmacokinetics, enhancing treatment in a dose-dependent fashion.

Original language	English (US)
Article number	6878
Journal	Scientific reports
Volume	4
DOIs	https://doi.org/10.1038/srep06878
State	Published - Nov 3 2014

Bibliographical note

Funding Information:
This study was funded by the GRL Project (NRF-2013K1A1A2A02050115), the GiRC (NRF-2012K1A1A2A01055811), and the Intramural Research Program of KIST.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/srep06878

OpenUrl availability

Full text

Cite this

@article{5b0433a88f874b92a7a269d784012050,

title = "Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA",

abstract = "Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and possibly synergistic mechanisms. In this respect, glycol chitosan (GC)-based nanoparticles (CNPs) serve as an effective platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy by overcoming resistance. Herein, DOX-encapsulated CNPs (DOX-CNPs) or Bcl-2 siRNA-encapsulated CNPs (siRNA-CNPs) exhibited similar physicochemical properties, including size, surface properties and pH sensitive behavior, regardless of the different physical features of DOX and Bcl-2 siRNA. We confirmed that the CNP platform applied to two different types of drugs results in similar in vivo biodistribution and pharmacokinetics, enhancing treatment in a dose-dependent fashion.",

author = "Yoon, {Hong Yeol} and Sejin Son and Lee, {So Jin} and You, {Dong Gil} and Yhee, {Ji Young} and Park, {Jae Hyung} and Maggie Swierczewska and Seulki Lee and Kwon, {Ick Chan} and Kim, {Sun Hwa} and Kwangmeyung Kim and Pomper, {Martin G.}",

note = "Funding Information: This study was funded by the GRL Project (NRF-2013K1A1A2A02050115), the GiRC (NRF-2012K1A1A2A01055811), and the Intramural Research Program of KIST.",

year = "2014",

month = nov,

day = "3",

doi = "10.1038/srep06878",

language = "English (US)",

volume = "4",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles

T2 - Sequential delivery of doxorubicin and Bcl-2 siRNA

AU - Yoon, Hong Yeol

AU - Son, Sejin

AU - Lee, So Jin

AU - You, Dong Gil

AU - Yhee, Ji Young

AU - Park, Jae Hyung

AU - Swierczewska, Maggie

AU - Lee, Seulki

AU - Kwon, Ick Chan

AU - Kim, Sun Hwa

AU - Kim, Kwangmeyung

AU - Pomper, Martin G.

N1 - Funding Information: This study was funded by the GRL Project (NRF-2013K1A1A2A02050115), the GiRC (NRF-2012K1A1A2A01055811), and the Intramural Research Program of KIST.

PY - 2014/11/3

Y1 - 2014/11/3

N2 - Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and possibly synergistic mechanisms. In this respect, glycol chitosan (GC)-based nanoparticles (CNPs) serve as an effective platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy by overcoming resistance. Herein, DOX-encapsulated CNPs (DOX-CNPs) or Bcl-2 siRNA-encapsulated CNPs (siRNA-CNPs) exhibited similar physicochemical properties, including size, surface properties and pH sensitive behavior, regardless of the different physical features of DOX and Bcl-2 siRNA. We confirmed that the CNP platform applied to two different types of drugs results in similar in vivo biodistribution and pharmacokinetics, enhancing treatment in a dose-dependent fashion.

AB - Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and possibly synergistic mechanisms. In this respect, glycol chitosan (GC)-based nanoparticles (CNPs) serve as an effective platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy by overcoming resistance. Herein, DOX-encapsulated CNPs (DOX-CNPs) or Bcl-2 siRNA-encapsulated CNPs (siRNA-CNPs) exhibited similar physicochemical properties, including size, surface properties and pH sensitive behavior, regardless of the different physical features of DOX and Bcl-2 siRNA. We confirmed that the CNP platform applied to two different types of drugs results in similar in vivo biodistribution and pharmacokinetics, enhancing treatment in a dose-dependent fashion.

UR - http://www.scopus.com/inward/record.url?scp=84930683143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930683143&partnerID=8YFLogxK

U2 - 10.1038/srep06878

DO - 10.1038/srep06878

M3 - Article

C2 - 25363213

AN - SCOPUS:84930683143

SN - 2045-2322

VL - 4

JO - Scientific reports

JF - Scientific reports

M1 - 6878

ER -

Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this